Further, subgroup analysis showed that an increased UCP1 level favored longer OS in patients with ovarian cancer at stage 2 and grade 3, an increased UCP2 level favored longer OS in patients with ovarian cancer at stage 1, 2, 3 and grade 3, an increased UCP3 level favored longer OS in patients with ovarian cancer at stage 3 and grade 2, 3, an increased UCP3 level favored longer OS in patients with ovarian cancer at stage 3, grade 2, 3, and an increased UCP5 favored longer OS in patients with ovarian cancer at stage1, 2, 4, grade 2, 3. This evidence concerns the gene UCP2 and ovarian cancer.